Francois Guilhot
Overview
Explore the profile of Francois Guilhot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
10792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guilhot F, Hehlmann R
Blood
. 2024 Nov;
145(9):910-920.
PMID: 39486043
Long-term outcomes with tyrosine kinase inhibitors (TKIs) show that their impact on chronic myeloid leukemia (CML) is sustained as shown by 13 studies with 5- to 14-year-follow-up, and numerous shorter-term...
2.
3.
Roy L, Chomel J, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, et al.
Br J Haematol
. 2022 Oct;
200(2):175-186.
PMID: 36214090
Superior rates of deep molecular response (DMR) have been reported with the combination of tyrosine kinase inhibitors and pegylated-interferon-alpha (Peg-IFN) in patients with newly diagnosed chronic phase-chronic myeloid leukaemia (CP-CML)....
4.
Dohner H, Malcovati L, Ossenkoppele G, Hochhaus A, Vannucchi A, Bullinger L, et al.
Hemasphere
. 2021 Sep;
5(9):e635.
PMID: 34476345
No abstract available.
5.
Rousselot P, Mollica L, Guilhot J, Guerci A, Nicolini F, Etienne G, et al.
Br J Haematol
. 2021 Jul;
194(2):393-402.
PMID: 34195988
Dasatinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor approved for patients with chronic myeloid leukaemia (CML). Dasatinib 100 mg per day is associated with an increased risk of pleural effusion...
6.
Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler A, Maloisel F, Rea D, et al.
Leukemia
. 2021 Jan;
35(8):2332-2345.
PMID: 33483613
The STI571 prospective randomised trial (SPIRIT) French trial is a four-arm study comparing imatinib (IM) 400 mg versus IM 600 mg, IM 400 mg + cytarabine (AraC), and IM 400 ...
7.
Cayssials E, Torregrosa-Diaz J, Leleu X, Guilhot F, Chomel J
Cancer
. 2020 Oct;
127(6):976-978.
PMID: 33095912
No abstract available.
8.
Pfirrmann M, Clark R, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al.
Leukemia
. 2020 Jul;
34(8):2138-2149.
PMID: 32601376
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our...
9.
Cayssials E, Torregrosa-Diaz J, Gallego-Hernanz P, Tartarin F, Systchenko T, Maillard N, et al.
Cancer
. 2020 May;
126(15):3438-3447.
PMID: 32459375
Background: Long-term treatment-free remission (TFR) represents a new goal for chronic myeloid leukemia (CML). In clinical practice, tyrosine kinase inhibitor (TKI) dose reductions can be considered a means of preventing...
10.
Hahnel T, Baldow C, Guilhot J, Guilhot F, Saussele S, Mustjoki S, et al.
Cancer Res
. 2020 Feb;
80(11):2394-2406.
PMID: 32041835
Recent clinical findings in patients with chronic myeloid leukemia (CML) suggest that the risk of molecular recurrence after stopping tyrosine kinase inhibitor (TKI) treatment substantially depends on an individual's leukemia-specific...